PCMU
VRTX icon

Paragon Capital Management (Utah)’s Vertex Pharmaceuticals VRTX Stock Holding History

Paragon Capital Management (Utah)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
+2,273
New +$1.01M 0.84% 45
2023
Q1 		– Sell
-3,576
Closed -$1.03M – 83
2022
Q4 		$1.03M Sell
3,576
-2,559
-42% -$780K 0.96% 45
2022
Q3 		$1.78M Sell
6,135
-37
-0.6% -$10.6K 1.74% 13
2022
Q2 		$1.74M Buy
+6,172
New +$1.65M 1.76% 14

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

Paragon Capital Management (Utah)'s VRTX Position: Q2 2026 in Review

Paragon Capital Management (Utah) opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 2,273 shares worth $1.13M. The stake represents 0.84% of the portfolio and ranks #45 among its holdings. This is a return to the name: Paragon Capital Management (Utah) previously reported a position in VRTX as recently as Q4 2022.

Paragon Capital Management (Utah) first reported a position in VRTX in Q2 2022 and has held it in 4 quarters since. The position peaked at $1.78M in Q3 2022. 374 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Paragon Capital Management (Utah) held 2,273 shares of Vertex Pharmaceuticals worth $1.13M as of Q2 2026.
  • Vertex Pharmaceuticals was a new Paragon Capital Management (Utah) position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.84% of Paragon Capital Management (Utah)'s portfolio in Q2 2026, its #45 holding.
  • Paragon Capital Management (Utah) first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
  • Paragon Capital Management (Utah)'s Vertex Pharmaceuticals position peaked at $1.78M in Q3 2022.
  • 374 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Paragon Capital Management (Utah)'s 13F filing for Q2 2026, filed 22 Jul 2026.